Table 2.
Clinicopathological characteristics associated with pCR
| Characteristic | Total | Non-pCR, n (%) | pCR, n (%) | Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|---|---|---|---|
| χ2 | p-value | OR | 95% CI | p-value | ||||
| Age at diagnosis (yr) | ||||||||
| < 50 | 396 | 328 (82.8) | 68 (17.2) | 0.171 | 0.680 | - | - | |
| ≥ 50 | 294 | 247 (84.0) | 47 (16.0) | |||||
| Menopausal status | ||||||||
| Premenopausal | 438 | 367 (83.8) | 71 (16.2) | 0.180 | 0.671 | - | - | |
| Postmenopausal | 252 | 208 (82.5) | 44 (17.5) | |||||
| cT | ||||||||
| T1 | 49 | 37 (75.5) | 12 (24.5) | 10.124 | 0.018 | Reference | 0.036 | |
| T2 | 498 | 408 (81.9) | 90 (18.1) | 0.594 | 0.281–1.255 | 0.172 | ||
| T3 | 105 | 93 (88.6) | 12 (11.4) | 0.319 | 0.123–0.827 | 0.019 | ||
| T4 | 37 | 36 (97.3) | 1 (2.7) | 0.103 | 0.012–0.872 | 0.037 | ||
| cN | ||||||||
| N0 | 127 | 95 (74.8) | 32 (25.2) | 14.014 | 0.003 | Reference | 0.014 | |
| N1 | 345 | 285 (82.6) | 60 (17.4) | 0.801 | 0.473–1.354 | 0.407 | ||
| N2 | 49 | 41 (83.7) | 8 (16.3) | 0.599 | 0.238–1.510 | 0.277 | ||
| N3 | 168 | 153 (91.1) | 15 (8.9) | 0.329 | 0.163–0.664 | 0.002 | ||
| HR (%) | ||||||||
| < 10 | 244 | 168 (68.9) | 76 (31.1) | 56.994 | < 0.001 | Reference | < 0.001 | |
| ≥ 10 | 446 | 407 (91.3) | 39 (8.7) | 0.228 | 0.144–0.361 | < 0.001 | ||
| Ki-67 (%) | ||||||||
| < 20 | 54 | 50 (92.6) | 4 (7.4) | 3.632 | 0.057 | - | - | |
| ≥ 20 | 635 | 524 (82.5) | 111 (17.5) | |||||
| HER2 | ||||||||
| 0 | 196 | 151 (77.0) | 45 (23.0) | 7.805 | 0.005 | Reference | - | |
| IHC 1+/2+(FISH−) | 494 | 424 (85.8) | 70 (14.2) | 0.800 | 0.505–1.265 | 0.340 | ||
CI, confidence interval; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IHC, immunohistochemistry; OR, odds ratio; pCR, pathological complete response.